Navigation Links
DaVita Clinical Research Completes Record Number of Renal Trials in 2007
Date:5/8/2008

Nation's Largest Renal Research Network Completes 13 Phase-I Clinical

Trials; Reports Another 34 Active Trials in Late Stage Development

EL SEGUNDO, Calif., May 8 /PRNewswire/ -- DaVita Clinical Research(R) (DCR), a Phase I-IV clinical trial research service business specializing in renal-related drug and device research and development for FDA approval, reports it completed 13 Phase-I clinical trials in 2007 and has another 34 active trials in late stage drug development-a company record.

(Logo: http://www.newscom.com/cgi-bin/prnh/20020729/DAVITALOGO)

DCR(R), through its commitment to quality, timely and accurate clinical trials, plays a valuable role by partnering with physicians, pharmaceutical and biotechnology companies to develop and progress new drug therapies for patients diagnosed with chronic kidney disease (CKD). The increase in completed and late stage trials also serves as an indication of continued innovation and investment for end stage renal disease (ESRD) research.

"The recent DaVita Clinical Research accomplishments can be attributed to our continuous research quality index measurements and commitment to service excellence," said Chris Rucker, DCR Vice President and General Manager. "These values serve as a catalyst for our research objectives, and allow us to participate in the advancement of renal knowledge and practice."

DCR has nearly two decades of experience in conducting Phase I-IV clinical trials, and is the nation's largest renal research network dedicated to providing and supporting clinical and data research. DCR provides Phase-I renal studies services including renal, Hepatic, CV, Dermatology and Endocrine subjects, Pharmacokinetics, Pharmacodynamics and drug interactions. Phase II- IV renal studies services include pre ESRD and ESRD subjects, clinical efficacy and safety, special populations and post marke
'/>"/>

SOURCE DaVita Clinical Research
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Globus Medical Completes Enrollment Of SECURE(R)-C Cervical Artificial Disc Clinical Trial
2. Siemens and LabCorp Enter Agreement to Co-Develop New Clinical Diagnostic Tests
3. Vion Pharmaceuticals Announces Initiation of Clinical Trial of Cloretazine(R) (VNP40101M) in Combination with Cytarabine
4. BiPar Sciences Expands Phase 2 Clinical Trials of BSI-201, a Novel DNA Repair Inhibitor, in Ovarian Cancer
5. Go Healthy Initiates Additional Clinical Tests on Cholesterade
6. Arena Pharmaceuticals, Inc. Announces Initiation of Phase 1 Clinical Trial of Drug Candidate Under Partnership with Taisho Pharmaceutical Co., Ltd.
7. Johnson & Johnson to Provide Webcast Presentation of Tapentadol Phase 3 Clinical Data Presented at American Pain Societys Annual Meeting
8. XTENT Announces Clinical Trial Data to be Presented at Annual EuroPCR Meeting Next Week
9. NKTR-118 Shows Substantial Oral Bioavailability and Extended Half-Life in Phase 1 Clinical Data Presented at American Pain Society Meeting
10. Patients Treated with Risperidone Long-Acting Injection had a Significantly Longer Time to Relapse Compared to Quetiapine in International Clinical Study
11. Association of Clinical Research Organizations (ACRO) to Help Lead Clinical Trials Transformation Initiative
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/22/2014)...  Cephasonics, a technology-innovation leader with a game-changing embedded-ultrasound ... Ultrasound Box™-1), the first product in a new family ... Cephasonics for purchase by companies to rebrand with their ... showcasing the cQUB-1 for the first time at CMEF ... Chongqing, China from October 23 to 26. ...
(Date:10/22/2014)... 22, 2014  Quest Diagnostics (NYSE: DGX ... today announced that its Board of Directors has elected ... effective December 1, 2014. Including Dr. Leiden, the Board ... Chairman, President and CEO of Vertex Pharmaceuticals.   Dr. ... commercial experience in the pharmaceutical and biotechnology industries as ...
(Date:10/22/2014)... 22, 2014 Antigen Discovery Inc. (ADi), a ... , announced the receipt of a National Institutes of ... from the National Institute of Dental and Craniofacial Research (NIDCR). ... a Pan-HIV Protein Microarray Chip, which will contain every ... and aid in the development of safe and effective ...
Breaking Medicine Technology:Cephasonics Launches the cQUB-1, First Product in New Family of cQUB White-Label Ultrasound Systems Targeted at Medical Applications 2Cephasonics Launches the cQUB-1, First Product in New Family of cQUB White-Label Ultrasound Systems Targeted at Medical Applications 3Quest Diagnostics Adds Jeffrey M. Leiden, M.D., Ph.D., to Board of Directors 2Quest Diagnostics Adds Jeffrey M. Leiden, M.D., Ph.D., to Board of Directors 3Biomarker Discovery Company, Antigen Discovery Inc., Awarded an NIH Phase I Small Business Innovation Research Grant to Develop a Pan-HIV Protein Microarray Chip 2
... 2011  Seventeen of the 19 medical-surgical suppliers and healthcare ... 25 for 2011 work with GHX to automate and ... them achieve high-quality patient care at optimal economic cost. ... and providers recognized by Gartner in the Top 25 ...
... 2011 ULURU Inc. (NYSE AMEX: ... of the previously announced European license for Altrazeal®, with a ... Zealand. Extending the European territory to include ... is a common registration process and the marketing strategy and ...
Cached Medicine Technology:GHX Salutes 17 Healthcare Organizations That Use Its Technology for Inclusion on a Leading Analyst Firm's 2011 Healthcare Supply Chain Top 25 List 2ULURU Inc. Extends the European Altrazeal® License to Include Australia and New Zealand 2ULURU Inc. Extends the European Altrazeal® License to Include Australia and New Zealand 3
(Date:10/22/2014)... 2014 The Louis W. ... dedicated to distribute health information technology innovation to ... announced the development of six key guiding principles ... receiving healthcare. These are an expansion of the ... care that is respectful of and responsive to ...
(Date:10/22/2014)... 2014 Best Cheap Hosting USA is ... The site has recently announced that iPower ( http://www.best-cheap-hosting-usa.com/go/iPower/ ... people from around the world. , “iPower is one ... and is providing various kinds of useful products for ... on offering excellent customer service and a number of ...
(Date:10/22/2014)... 2014 Lintelus, Inc., an event software ... of Sales, will be speaking on the subject of ... on October 28, at the Holiday Inn in New ... as well as a Tech Demo at 12:45pm, to ... a more engaging event experience. , The Annual Meetings ...
(Date:10/22/2014)... HealthDay Reporter , TUESDAY, Oct. 21, ... (IVF) are only about half as likely as white women ... research indicates, and the racial disparity persists even when donor ... of white patients became pregnant after IVF, compared to about ... IVF cycles over two years to tease out the impact ...
(Date:10/22/2014)... -- Measures taken by Firestone officials at the company,s ... limited the spread of the disease there and could ... Rubber Co. provides health services to about 80,000 employees, ... communities. Between Aug. 1 and Sept. 23, there ... 80,000 people. That incidence rate of 0.09 percent was ...
Breaking Medicine News(10 mins):Health News:The Sullivan Institute for Healthcare Innovation Announces Release of Guiding Principles for Patient Experience-Centered Care 2Health News:Best Cheap Hosting USA Has Recently Announced The Best Cheap Web Hosting Companies In 2014 2Health News:Jay Cormier, Sr. Vice President of Sales for Lintelus, Speaks about Event Technology Integration at Meetings Technology Expo in NYC 2Health News:Black Women Fare Worse With Fertility Treatments, Study Says 2Health News:Black Women Fare Worse With Fertility Treatments, Study Says 3Health News:Tire Company Sets Standard for Ebola Care in Liberia: CDC 2
... May 15 /PRNewswire-FirstCall/ - CRH Medical Corporation,(CRM:TSX-V) announced today ... Bay Shore, Long Island. This Center is the Company,s ... new markets that CRH has targeted for,expansion. The opening ... 2008 bringing the Company,s total number of Centers to ...
... lead unhealthy lifestyles are more likely to suffer from ... population-based study of more than 5,000 men and women ... journal BJU International. Researchers hope the results will help ... can be managed more effectively. , According to ...
... Revenue Increased 70.9% to $9.2 Million, CHENGDU, ... (OTC Bulletin Board: TYNP), a manufacturer and,supplier of ... today announced fiscal results for its third quarter ... quarter of 2008 increased 70.9% to approximately,$9.2 million ...
... to be Webcast Live at 2:00 p.m. ET Thursday, ... Inc.,(Nasdaq: CYNO ), a leading developer and manufacturer ... announced that its senior,management will present at the 2008 ... the Hilton New York., Cynosure,s presentation will be ...
... MONTVALE, N.J., May 15 Pain is a ... are an important option,for these patients. Physicians must ... the best outcomes for their patients., To ... the proper,opioid analgesic, the dual journals Current Clinical ...
... mouse model hint of new treatment strategies for the disease ... fat, the kind often found in baked and fried goods, ... The finding by University of California, Los Angeles, scientists is ... mouse model that closely mimics human cancer. , The fat ...
Cached Medicine News:Health News:CRH Medical Corporation opens Center in New York 2Health News:Obesity and unhealthy lifestyles linked to more complex urinary problems 2Health News:Obesity and unhealthy lifestyles linked to more complex urinary problems 3Health News:Obesity and unhealthy lifestyles linked to more complex urinary problems 4Health News:Tianyin Pharmaceutical Co., Inc. Announces Third Quarter 2008 Financial Results 2Health News:Tianyin Pharmaceutical Co., Inc. Announces Third Quarter 2008 Financial Results 3Health News:Tianyin Pharmaceutical Co., Inc. Announces Third Quarter 2008 Financial Results 4Health News:Tianyin Pharmaceutical Co., Inc. Announces Third Quarter 2008 Financial Results 5Health News:Tianyin Pharmaceutical Co., Inc. Announces Third Quarter 2008 Financial Results 6Health News:Tianyin Pharmaceutical Co., Inc. Announces Third Quarter 2008 Financial Results 7Health News:Tianyin Pharmaceutical Co., Inc. Announces Third Quarter 2008 Financial Results 8Health News:Tianyin Pharmaceutical Co., Inc. Announces Third Quarter 2008 Financial Results 9Health News:Tianyin Pharmaceutical Co., Inc. Announces Third Quarter 2008 Financial Results 10Health News:Cynosure to Present at 2008 Citi Investment Research Global Health Care Conference 2Health News:Treat Your Patients' Pain Effectively 2Health News:Lowering Dietary Fat May Help Prevent Prostate Cancer 2
... face is the most widely used contrast sensitivity ... four (4) rows of sine-wave gratings. At the ... these gratings test the spatial frequencies of 3, ... a full contrast sensitivity curve, which is very ...
The Wills Eye Manual, Fourth Edition has been updated to include the newest drugs, procedures, and treatment protocols. Clinicians will have instant access to current information on diagnosis and tre...
... those involved with healthcare decisions to keep ... evidence in their field of interest - ... as the volume of evidence increases. Cochrane ... best single source available for continually updated ...
... Clinical Orthopedics 2007 includes ... therapeutic and rehab info as ... text is very extensive, it ... information. Great for any primary ...
Medicine Products: